Home › Merck Provides Update on Odanacatib Development Program
 

Keywords :   


Merck Provides Update on Odanacatib Development Program

2016-09-02 13:00:00| Merck.com - Research & Development News

Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that it is discontinuing the development of odanacatib, Mercks investigational cathepsin K inhibitor for osteoporosis, and will not seek regulatory approval for its use. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558orInvestors:Teri Loxam, 908-740-1986 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: development program update merck

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
05.11Tropical Storm Rafael Graphics
05.11Tropical Storm Rafael Wind Speed Probabilities Number 7
05.11Tropical Storm Rafael Public Advisory Number 7
05.11Summary for Tropical Storm Rafael (AT3/AL182024)
05.11Tropical Storm Rafael Forecast Advisory Number 7
05.11Boeing strike ends as workers back 38% pay rise deal
05.11Tropical Storm Rafael Public Advisory Number 6A
05.11Summary for Tropical Storm Rafael (AT3/AL182024)
More »